One important metric to look for in a stock is an 80 or higher Relative Strength Rating. MoonLake Immunotherap cleared that benchmark Tuesday, with a jump from 78 to 82 Tuesday.
Hone Your Stock-Picking Skills By Focusing On These Factors
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
History shows that the best-performing stocks typically have an 80 or higher RS Rating as they launch their biggest runs.
MoonLake Immunotherap is working on a cup with handle with a 52.88 entry. See if it can clear the breakout price in heavy trading.
The company showed 0% EPS growth in its most recent report. Revenue gains came in at 0%. Look for the next report on or around Aug. 7.
The company earns the No. 203 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
